212 related articles for article (PubMed ID: 23565676)
1. Human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Nahta R
Expert Opin Biol Ther; 2013 Jul; 13(7):949-52. PubMed ID: 23565676
[TBL] [Abstract][Full Text] [Related]
2. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
Janjigian YY; Braghiroli MI
Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
O'Sullivan CC; Connolly RM
Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
[TBL] [Abstract][Full Text] [Related]
4. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
[TBL] [Abstract][Full Text] [Related]
5. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
6. Targeting HER2 in Advanced Breast Cancer.
Zhu X; Joy AA
Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
[TBL] [Abstract][Full Text] [Related]
7. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.
Singh JC; Jhaveri K; Esteva FJ
Br J Cancer; 2014 Nov; 111(10):1888-98. PubMed ID: 25025958
[TBL] [Abstract][Full Text] [Related]
9. Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
Molina-Garrido MJ; Guillen-Ponce C; Mora-Rufete A
Anticancer Agents Med Chem; 2014 Jun; 14(5):639-45. PubMed ID: 23438846
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy in HER2-Positive Breast Cancer.
Thill M; Kraft C; Friedrich M
Oncol Res Treat; 2016; 39(5):295-302. PubMed ID: 27173915
[TBL] [Abstract][Full Text] [Related]
11. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
12. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
13. Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.
Soleja M; Rimawi MF
Curr Probl Cancer; 2016; 40(2-4):117-129. PubMed ID: 27839746
[TBL] [Abstract][Full Text] [Related]
14. Next-generation targeted agents in HER2-positive metastatic breast cancer.
Perez EA
Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
[No Abstract] [Full Text] [Related]
15. Improving treatment of HER2-positive cancers: opportunities and challenges.
Stern HM
Sci Transl Med; 2012 Mar; 4(127):127rv2. PubMed ID: 22461643
[TBL] [Abstract][Full Text] [Related]
16. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer.
Lv Q; Meng Z; Yu Y; Jiang F; Guan D; Liang C; Zhou J; Lu A; Zhang G
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983617
[TBL] [Abstract][Full Text] [Related]
18. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Zhang B; Hurvitz S
Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
Callahan R; Hurvitz S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):37-43. PubMed ID: 21500375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
